TransCode Therapeutics, Inc. - RNAZ STOCK NEWS

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) will attend and present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Michael Dudley will discuss the company's RNA-based cancer treatments, focusing on its lead candidate, TTX-MC138, which aims to enter its First in Human clinical trial in 2022. The presentation is scheduled for January 10, 2022, at 7:00 AM ET and will be webcast, with an archived recording available for 90 days on TransCode's website.

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) announced its participation at the MedInvest Oncology Investor Conference. CEO Michael Dudley will present the company's RNA-based advancements in cancer treatment, including their lead candidate, TTX-MC138, targeting metastatic cancer with a first human trial expected in mid-2022. The presentation is scheduled for December 7th at 2:50 PM EST and will be available via webcast. TransCode aims to improve outcomes for various cancers, responsible for approximately 90% of cancer deaths globally.

TransCode Therapeutics (RNAZ) reported progress in its RNA oncology initiatives and released its Q3 2021 financials. The company anticipates filing an eIND for TTX-MC138 by mid-2022. Extensive clinical data from microdosing studies supports the efficacy of TTX-MC138, designed for metastatic tumors. Financially, the company reported cash and equivalents of approximately $22.5 million, up from $0.8 million year-over-year, with significant increases in R&D and G&A expenses. Net loss for Q3 2021 was approximately $2.3 million, or $0.20 per share, and the company expects to continue incurring losses.

TransCode Therapeutics, Inc. (RNAZ) has appointed Dr. Zdravka Medarova as Chief Technology Officer, effective October 1, 2021. A scientific co-founder, Dr. Medarova has been on the advisory board since 2016 and brings expertise in RNA oncology, specifically in developing nanotechnology for RNA delivery. Her leadership is expected to enhance the TTX delivery platform, pivotal for TransCode's cancer treatment innovations. The company focuses on treating metastatic cancers, which account for approximately 90% of cancer deaths globally, with potential first-in-human studies ahead.

TransCode Therapeutics announced the publication of preclinical research supporting its lead candidate, TTX-MC138, in Cancer Nanotechnology. The study demonstrated that TTX-MC138 effectively targets metastatic lesions in models of metastatic breast cancer. Results showed successful biodistribution and pharmacokinetics, with TTX-MC138 accumulating in metastatic areas when administered intravenously. The company plans to submit an exploratory IND application in Q1 2022 for a Phase 0 study to establish clinical proof-of-concept, utilizing new microdosing PET-MRI methods to further advance its RNA delivery platform.

TransCode Therapeutics (RNAZ) announced significant business progress and Q2 2021 financial results, underscoring the impact of its IPO, which generated $28.8 million. The company aims to advance its RNA delivery platform, targeting metastatic tumors with its lead candidate, TTX-MC138, expected to enter clinical trials in 2022. Recent highlights include a $2.3 million NIH grant for TTX-MC138 and key staff appointments. As of June 30, 2021, cash totaled approximately $80K, with expectations to fund operations through 2022, although operational losses are anticipated to increase substantially.

TransCode Therapeutics (Nasdaq: RNAZ) has secured a $2.3 million Fast-Track SBIR grant from the NIH to advance the clinical evaluation of TTX-MC138, aimed at treating metastatic solid tumors. This grant will help fund a first-in-human study targeting metastatic breast cancer, with an eIND application planned for Q1 next year. TTX-MC138 targets MicroRNA-10b, linked to metastatic disease and demonstrated preclinical success in reducing metastatic cancer in murine models. TransCode seeks to leverage its TTX platform for broader therapeutic applications in oncology.

TransCode Therapeutics (Nasdaq: RNAZ) has successfully closed its initial public offering of 7,187,500 shares at $4.00 each, raising gross proceeds of $28.75 million. The offering included the full exercise of the underwriters' over-allotment option. Proceeds are earmarked for testing related to an Investigational New Drug application for TTX-MC138, its lead cancer therapeutic candidate, and for strategic expansion of its drug portfolio. The offering began trading on July 9, 2021, under the symbol RNAZ.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has priced its initial public offering (IPO) of 6,250,000 shares at $4.00 per share, aiming for gross proceeds of $25 million. The underwriters have a 45-day option to buy an additional 937,500 shares. Proceeds will fund the Phase 0 trial of lead candidate TTX-MC138, development of its drug portfolio, and general corporate purposes. Trading is set to begin on July 9, 2021, with closing expected on July 13, 2021. ThinkEquity manages the offering.